Bausch + Lomb (NYSE:BLCO) Price Target Lowered to $15.00 at HC Wainwright

Bausch + Lomb (NYSE:BLCO - Free Report) had its target price reduced by HC Wainwright from $20.00 to $15.00 in a research report sent to investors on Friday morning, Marketbeat reports. They currently have a buy rating on the stock.

A number of other research firms have also weighed in on BLCO. Evercore ISI reduced their target price on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research note on Thursday, May 1st. Citigroup reduced their price target on Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating for the company in a research report on Thursday, May 1st. Stifel Nicolaus cut their target price on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a research note on Thursday, April 3rd. Royal Bank of Canada decreased their price target on shares of Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, April 4th. Finally, Wells Fargo & Company reduced their price objective on shares of Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $15.50.

Bausch + Lomb Trading Up 3.9 %

NYSE BLCO traded up $0.43 on Friday, hitting $11.33. 253,553 shares of the stock were exchanged, compared to its average volume of 649,616. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60. Bausch + Lomb has a 52-week low of $10.45 and a 52-week high of $21.69. The firm has a market capitalization of $4.00 billion, a P/E ratio of -12.48, a P/E/G ratio of 0.85 and a beta of 0.58. The stock has a fifty day moving average price of $13.72 and a two-hundred day moving average price of $16.75.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.10). The firm had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business's revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.07 earnings per share. Research analysts forecast that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Institutional Trading of Bausch + Lomb

Several institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp raised its holdings in shares of Bausch + Lomb by 5.6% during the third quarter. State Street Corp now owns 28,450 shares of the company's stock worth $549,000 after purchasing an additional 1,510 shares during the last quarter. Barclays PLC acquired a new position in shares of Bausch + Lomb in the 3rd quarter valued at about $5,797,000. FNY Investment Advisers LLC purchased a new stake in shares of Bausch + Lomb in the fourth quarter worth about $72,000. Ellsworth Advisors LLC acquired a new position in Bausch + Lomb in the fourth quarter valued at approximately $665,000. Finally, Blue Trust Inc. boosted its position in Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after purchasing an additional 1,004 shares in the last quarter. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.